KDM1A
Lysine-specific histone demethylase 1A
As of the edition of 20 October 2026, KDM1A (lysine-specific histone demethylase 1A, UniProt O60341) has 9 drugs tested at it and 8 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O60341
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 130
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Inherited and neonatal; Urinary and reproductive; Digestive system; Immune system; Mental health
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bomedemstat | Active | Phase 3 | none listed |
| Iadademstat | Stopped | Phase 2 | none listed |
| Pulrodemstat | Stopped | Phase 2 | none listed |
| Seclidemstat | Stopped | Phase 2 | none listed |
| INCB-059872 | Stopped | Phase 2 | none listed |
| GSK2879552 | Stopped | Phase 2 | none listed |
| Jbi-802 free base | Active | Phase 2 | none listed |
| TAS1440 | Stopped | Phase 1 | none listed |
| Vafidemstat | Status not established | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| GSK | Route A |
| Bristol Myers Squibb | Route A |
| Incyte | Route A |
The other 5 companies at KDM1A
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at KDM1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.